Gastrocrom (cromolyn) / Viatris - LARVOL DELTA

Hereditary Alpha Tryptasemia and Chronic Lymphocytic Leukemia Presenting As New Onset Refractory Erythema (ACAAI 2023) - "Treatment with Gastrocrom and famotidine resulted in minimal response...He was referred to allergy and initiated on high dose cetirizine and montelukast with ∼20% improvement...Team approach recommended Zanubrutinib (Bruton's tyrosine kinase [BTK] inhibitor) treatment for CLL, recognizing that symptoms could be paraneoplastic and that BTK inhibitors inhibit mast cell degranulation and cytokine production (2). After 12 weeks, he reported 80% improvement in all symptoms with corresponding decrease in tryptase (15.9 μg/L) and reduction of allergy medications. Discussion This case of HAT and CLL co-occurring and presenting with mast cell-like disease symptoms refractory to mast cell disease therapies underscores the importance of vigilance for underlying malignancy and corresponding treatment."

Allergy • Asthma • Chronic Lymphocytic Leukemia • Dermatology • Fatigue • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Nasal Polyps • Oncology • Otorhinolaryngology • Pain • Pulmonary Disease • Rare Diseases • Respiratory Diseases • JAK2 • TPSAB1

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Northwestern University | Recruiting ➔ Completed | Trial primary completion date: Jun 2022 ➔ Apr 2022

Trial completion • Trial primary completion date • Gynecology • Musculoskeletal Pain • Pain

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Northwestern University; Trial completion date: Jun 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022

Trial completion date • Trial primary completion date • Gynecology • Musculoskeletal Pain • Pain • Tryptase

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Northwestern University; Trial primary completion date: Jun 2020 ➔ Jun 2021

Trial primary completion date • Gynecology • Musculoskeletal Pain • Pain • Tryptase

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis (clinicaltrials.gov) - P4; N=24; Recruiting; Sponsor: University of Tennessee

New P4 trial • Biosimilar

"Yeah Gastrocrom was awful for me. Way too many side effects. Ketotifen. None! :)" (@melinaev_ya)

Adverse events

Cromolyn Detection of Silent Aspiration (clinicaltrials.gov) - P1; N=16; Terminated; Sponsor: University of California, San Francisco; Recruiting ➔ Terminated; Difficulty recruiting; Funding ended; interim analysis provided sufficient data for interpretation.

Trial termination